Tregs, known for their highly suppressive and hyperproliferative features in the TME, express heightened levels of CD25, CTLA4, GITR, OX40, ICOS, and neuropilin-1 and accumulate significantly during tumor development (4, 50, 65–70). The gene discussed is TNFRSF18; the disease is neoplasm.